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Abstract
Background
Pneumococcal conjugate vaccines (PCVs), PCV10 and PCV13, are currently used in differ-
ent countries. We have previously reported the effectiveness of PCV7, following its introduc-
tion in Israel and before PCVs were introduced in Palestine. Here, we extended the study
and compared the initial impact of PCV10 to that of PCV7/13.
Methods
Four cross-sectional surveys of S. pneumoniae carriage among children <5y through 2009–
2014 were preformed among two proximate populations, living under two distinct health
authorities, with different vaccination policies. In East-Jerusalem (EJ), PCV7 was imple-
mented in 2009 and replaced by PCV13 in late 2010, while in Palestine (PA), PCV10 was
implemented in 2011.
Results
A total of 1267 and 2414 children from EJ and PA were screened. In 2014, S. pneumoniae
was detected in 30.7% and 28.6% of the children in EJ and PA respectively Implementation
of both PCV7 (in EJ) and PCV10 (in PA) did not affect overall S. pneumoniae carriage, but
resulted in a significant decrease in the prevalence of vaccine-type strains. In the pre-vac-
cine era, VT7/VT13 strains consisted 47.0%/62.0% and 41.2%/54.8% of pneumococci in EJ
and PA, respectively. A 48.6% and 53.9% decrease in VT7 strains was observed within 3
years of PCV7 implementation in EJ (p = 0.001) and PCV10 in PA (p<0.0001), respectively.
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These vaccination policies also resulted in ~50% reduction in VT13-added serotypes espe-
cially 6A (from 11.0% to 0.0% (EJ) and 9.5% to 4.9% (PA)). Three years after PCV13 imple-
mentation in EJ, an additional 67% decrease in VT13 strains was observed, yet an increase
in serotype 3 was observed (0.0% to 3.4%, p = 0.056). While the prevalence of VT13 strains
decreased significantly during the study period, the overall carriage rate didn’t change signif-
icantly due to replacement with non-VT13 strains which comprised 89.8% and 70.7% of all
pneumococci, in EJ and in PA respectively in the last study year.
Conclusions
Within the first three years following PCV implementation, we observed similar reductions in
carriage of VT10 and VT13 strains with either vaccination policies, with no effect on overall
carriage. Further follow-up is needed to compare the long-term effects.
Introduction
Pneumococcal diseases cause high rates of morbidity and mortality worldwide causing bacte-
rial meningitis, community-acquired pneumonia, acute otitis media, and sinusitis [1]. Naso-
pharyngeal (NP) colonization with S. pneumoniae is common in young children and serves as
the source of transmission between individuals in the community and as the first step towards
infection [2]. Moreover, understanding the dynamics of pneumococcal colonization following
PCV implementation in children will lead to better understanding and possible prediction of
the herd effects associated with PCV implementation [3]. The introduction of pneumococcal
conjugate vaccine (PCV) to the routine childhood vaccination had a dramatic impact on the
incidence of invasive pneumococcal disease (IPD) due to decrease in vaccine-type (VT) colo-
nization and infections [4]. Currently two PCVs are in use in different countries; PCV10 is
being used in several South American countries, Finland, the Netherlands and in Palestine,
covering serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. PCV13 is being used in the USA,
most European countries, several African countries, Australia and Israel [5]. PCV13 covers all
PCV10 serotypes and additionally, serotypes 3, 6A and 19A. Despite the greater number of
serotypes covered by PCV13, it is still controversial whether its impact on carriage and disease
are greater [6].
The Palestinian-Israeli Collaborative Research (PICR) group was established in 2009, by
independent Palestinian and Israeli researchers, and offers a golden opportunity to study vac-
cination effects and impacts in the region, where two closely related Palestinian populations
are governed by two distinct health authorities with different vaccination policies [7]. In this
study, we compare the effects of sequential PCV7/PCV13 to PCV10 implementation on Pales-
tinians living in East Jerusalem under Israeli health policy, vaccinated with PCV7/13 and
Palestinians living in the West Bank, under the Palestinian Authority health policy, vaccinated
with PCV10.
Materials and methods
Ethical approvals
The study was approved by the Institutional Review Boards (IRB) of Sheba Medical Center,
Maccabi Healthcare Services (MHS) and Al-Quds University. The parent of each participating
child provided a written informed consent before recruitment.
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PICR setting and study population
A population based study consisting of repeated cross-sectional surveillances was conducted
in two geographically proximate Palestinian populations which are under two different health
authorities and consequently under different vaccination policies. This setting was previously
described in detail [7]. In brief, Palestinian children (<5 years) and their accompanying parent
who visited their primary care pediatrician, either from East Jerusalem (EJ), which is under
Israeli Health Law, or from Palestinian cities in the West Bank governed by the Palestinian
Authority (PA) were enrolled if the parent agreed and signed an informed consent.
Vaccination policies in the two populations
In Israel, PCV7 was approved for use and introduced to the private market in 2007 and to the
pediatric national immunization program (NIP) in July 2009 in a 2+1 schedule with a 2 dose
catch-up. In November 2010, PCV13 gradually replaced PCV7 without catch-up.
In Palestine, until 2011, access to PCV was very limited. In 2011, PCV10 was introduced
through the Palestinian Ministry of Health to the pediatric NIP in a 2+1 schedule through pri-
mary care physicians. The vaccination was provided free of charge to all children under 2y by
the Palestinian Ministry of Health.
Study design and pneumococcal carriage screening
Four cross-sectional surveillance studies were conducted during May-July of 2009–2011 and
2014, results of three which have been previously reported [7]. The first surveillance, in 2009,
served as a baseline, pre-vaccination surveillance for both populations, before PCV was intro-
duced in either PA or EJ. The following two surveillances were conducted in the consecutive
years (2010–2011) and allowed to evaluate the impact and effects of PCV7 [7]. This update of
the study includes the forth surveillance, conducted in 2014, three and a half years after
PCV13 replaced PCV7 in EJ and three years after the introduction of PCV10 in PA. This sur-
veillance provided the opportunity to assess the initial effects of PCV10 compared to PCV13.
Children and their parents were screened for nasopharyngeal pneumococcal carriage as
previously described [7]. In brief, medical history data, including vaccination history, were col-
lected from the parents by a study coordinator and from the medical files by the physicians.
Swabs were transferred to the laboratory within 24 hours, where pneumococci were identified
and serotype was determined in two steps; initially latex agglutination test (StatenSerum Insti-
tute, Copenhagen, Denmark) was used to determine the serogroup, followed by PCR to deter-
mine the serotype.
Statistical analysis
Prevalence rates and proportions were calculated and compared using Chi-square or Fisher’s
exact test, as applicable. The Cochran-Armitage trend test was used to determine trends along
the study years. Additionally, comparison of VT13 prevalence between the two regions before
and after the implementation of the three different vaccines was applied using the Cochran–
Mantel–Haenszel test. All statistical analyses were performed using SAS 9.4 for Unix.
Results
Study population description
A total of 1267 and 2414 children from EJ and PA were screened in the four surveillance stud-
ies [7]. Each year, approximately 300 children were screened in EJ and 600 children were
screened in PA. A detailed description of the study population of the first three surveys (2009–
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2011) was previously reported [7, 8]. Here, we present an additional surveillance that took
place in 2014 in which 287 children from EJ and 643 children from PA were screened. Popula-
tion characteristics in this surveillance are similar to those in the 3 initial surveillances, with a
slightly higher proportion of males (54% and 59% in EJ and PA), approximately, 45% of the
children between 6 and 24 months and>15% of the children living in large households with
7+ household members, in both regions (S1 Table).
PCV coverage
During the first year of the study, in the pre-vaccine period, when PCV7 was approved and
available in the private market, but not yet implemented in the NIP, we found that only 2.7%
and 2.3% of the children in EJ and PA respectively received at least one dose of the vaccine,
and only 1.2% in EJ and 0.7% in PA received at least two doses. Within a year of implementing
PCV7 in EJ, the proportion of children <2 years old who received at least one vaccine dose
increased to 75%. In PA, PCV10 was not introduced until late 2011, the proportion of children
<2 years who received at least one dose of any PCV (PCV7 or PCV10) in PA before PCV10
implementation did not exceed 13%. This proportion increased to 85.5% three years after
implementing PCV10 in the vaccination program compared to 92% of children in EJ
(p = 0.03) (Table 1).
S. pneumoniae carriage, serotype distribution and replacement
Of all children screened, S. pneumoniae carriage was detected in 29.0% (100/345) of the chil-
dren in EJ and 36.0% (223/620) of children in PA in 2009 before PCV was introduced. This
carriage did not change significantly in EJ during the study period and ranged between 26.9%
and 30.7%. In PA, S. pneumoniae carriage decreased from 36.0% (223/620) to 28.8% (160/556)
(ptrend = 0.0092) during the first three study years (before PCV10 introduction), but did not
decrease further, three years after PCV10 was introduced (Fig 1). The overall S. pneumoniae
carriage among children during the whole study period was 28.9% in EJ and 31.8% in PA.
In the pre-vaccine study year, the proportion of VT strains among all pneumococcal isolates
was similar in the two populations, with VT7 strains constituting 47.0% of all isolates in EJ and
41.2% in PA (p = 0.33). VT10-added serotypes (1, 5, and 7F) were rarely carried (3/1130) dur-
ing all years in both populations. Prior to vaccine introduction in 2009, VT13-added serotypes
(3, 6A and 19A) constituted 14.0% (n = 14) in EJ and 13.6% (n = 30) in PA and non-VT13
serotypes constituted 38.0% (n = 38) of all S. pneumoniae in that year in EJ and 45.3%
(n = 100) in PA. Since the VT10-added serotypes were very rarely carried, the impact on VT7
carriage was identical to that on VT10; therefore, we report only the impact on VT10 and
VT13. During the first two years following PCV7 implementation in EJ, but not yet in PA, a
significant decrease in VT10 strains was observed in EJ (p = 0.0007), while no change was
observed in PA (p = 0.8914), as described previously [7].
Table 1. Vaccine coverage in study population by year and region.
Variable EJ PA
2009 2010 2011 2014 2009 2010 2011 2014
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
% vaccinated�1 dose 9 (2.7) 173 (55.6) 228 (70.4) 267 (93.0) 14 (2.3) 35 (5.9) 61 (11.0) 513 (79.8)
% vaccinated >2 doses 4 (1.2) 124 (39.9) 196 (60.5) 238 (82.9) 4 (0.7) 13 (2.2) 35 (6.3) 431 (67.5)
% of children<2years vaccinated�1 dose 6 (3.7) 141 (75.0) 168 (85.7) 161 (92.0) 11 (2.5) 18 (4.0) 54 (13.0) 382 (85.5)
% of vaccinated children >2yrs (�1 dose) 3 (1.7) 32 (26.0) 60 (46.9) 106 (94.6) 3 (1.6) 17 (11.6) 7 (5.1) 131 (66.8)
https://doi.org/10.1371/journal.pone.0206927.t001
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A further significant decrease in VT10 serotypes was observed three years after the intro-
duction of PCV13 in EJ, with prevalence of VT10 strains decreasing to 5.7% (n = 5) in 2014
(p = 0.0006). In PA, following introduction of PCV10 in 2011, the prevalence of VT10 sero-
types significantly decreased from 41.9% (n = 67) in 2011 to 19.0% (n = 35) by 2014
(p<0.0001) (Fig 1). Concurrently, carriage of non-VT13 serotypes, increased over the years
after introducing PCV7/13 in EJ and they gradually replaced VT13 serotypes. In PA, carriage
of non-VT13 serotypes did not change before PCV10 introduction (p = 0.2527), but 3 years
later the prevalence almost doubled, replacing VT13 serotypes (p<0.0001) (Fig 1).
When we assessed the rate of decrease in VT13 strains following the introduction of each of
the three vaccine introductions, a similar 50% reduction was observed within 3 years of imple-
mentation of either PCV7 or PCV10 and an additional reduction of 67% in VT13 strains was
observed after PCV13 introduction (Table 2). Overall, under the sequential PCV7/13 policy,
VT13 strains decreased by 83.5% during the whole study period (from 62.0% to 10.2%) in EJ,
but during the first two years following PCV7 implementation VT7 strains decreased by 48.7%
(from 47.0% to 24.1%), and following PCV13 implementation, within 3.5 years VT13 strains
decreased by another 67.1%. In PA, where PCV10 was implemented three years later, VT10
strains decreased by 54.7% (from 41.9% in 2011 to 19.0% in 2014) but interestingly the
VT13-added serotypes also decreased by 45% (p = 0.0258), this decrease was attributed to the
decrease in serotype 6A (Table 2).
While VT10 serotypes decreased significantly following implementation of any of the vac-
cines, these were replaced by non-VT13 serotypes. In EJ, VT10 serotypes were nearly elimi-
nated by 2014 with only a few isolates of serotypes 14, 23F, and 9V remaining. Yet, the group
of VT13-added serotypes (3, 6A and 19A) did not decrease significantly in EJ after the
Fig 1. Proportion of VT strains’ carriage among all S. pneumoniae isolates in the two populations. (A) In EJ. (B) In
PA. Dark grey represents the proportion of VT10 strains among all isolates. Stripes represent the proportion of
carriage of 6A serotype. White represents the proportion of carriage of 19A serotype. Black represents the proportion
of carriage of serotype 3, and Light grey represents the proportion of carriage of non-VT13 serotypes.
https://doi.org/10.1371/journal.pone.0206927.g001
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introduction of PCV13 (p = 0.536). The dynamics of each of these serotypes was different.
Serotype 6A decreased significantly, already following PCV7 introduction, and was completely
eliminated by 2014. Similarly, serotype 19A decreased somewhat following PCV7; from three
cases (3.0%) to one case (1.1%), though the number of cases are very small and statistical sig-
nificance was not obtained (p = 0.292), but no further decline was observed following PCV13
introduction. At the same time serotype 3 increased from 0 cases in 2009 to 3/88 (3.4%) in
2014, (p = 0.056) (Table 3). In PA, before PCV10 implementation, a relatively stable preva-
lence of VT10 and VT13-added serotypes was observed. Within three years following PCV10
implementation, a significant decrease in VT10, which was attributed to large decrease in sero-
types 6B, 23F and 19F, was observed (from 30.0% from the carriage in 2009 to 9.2% in 2014).
Interestingly, a decrease was also observed in the prevalence of two of the VT13-added sero-
types: 6A (from 10.6% (n = 17) to 4.9% (n = 9), p = 0.045) and 19A (from 3.8% (n = 6) to 1.6%
(n = 3), though not statistically significant). The prevalence of serotype 3 did not change in this
period (~4%).
Non-VT13 serotypes gradually replaced VT13 serotypes; therefore, overall carriage of S.
pneumonia did not change significantly in both regions. The proportion of non-VT13 strains
increased from 38.0% of all isolates in pre-PCV surveillance in 2009, to 89.8% three years after
the introduction of PCV13 in EJ (p<0.001). As for PA, the proportion of non-VT13 serotypes
increased from 39.4% in the pre-PCV period (2011) to 70.7% in 2014 (p<0.001). Table 4 pres-
ents the most common non-VT13 serotypes in both regions and their proportion among all
isolates during the four surveillance periods, as well as p-values of the change pre- to post-vac-
cine periods. By 2014, serotypes 19B/C, 11A/D, 22F, 25/38, 40, 21, 9N/L and 12F emerged in
EJ, while in PA, the non-VT13 serotypes that emerged 3 years following PCV10 implementa-
tion were 19B/C, 40, 23A and 7B/C.
Parental carriage
S. pneumoniae carriage among the parents was relatively rare, with 3.8% (n = 139/3681) of
parents detected as nasopharyngeal carriers in both regions. Overall, 18.3% (n = 23) of parent
strains belonged to VT10 serotypes in both regions. Serotypes 14, 19F and 23F constituted the
majority of VT10 serotypes (73.9%, n = 17). Parental strains that belonged to non-VT13 sero-
types constituted 67.5% (n = 27) and 72.1% (n = 62) in EJ and PA, respectively (Table 5). The
small sample size of parental strains did not allow us to assess PCV effect on parental carriage
or strain distribution. Sixty percent of the parents who were carriers, had a child who was also
Table 2. Proportion of VT13 decrease post PCV7/10/13 introduction.
2009 2010 2011 2014 Impact of PCV� P-value
VT7
N(% of SP)
EJ 47 (47.0) 24 (26.4) 21 (24.4) 5 (5.7) -48.7%
(2009 to 11)
<0.0001
VT10
N(% of SP)
PA 91 (41.2) 76 (38.4) 67 (41.9) 35 (19.0) -54.7%
(2011–14)
<0.0001
-50.0% PCV7
(2009–11)
<0.0001
VT13 EJ 62 (62.0) 32 (35.2) 27 (31.0) 9 (10.2)
N(% of SP) -67.1% PCV13
(2011–14)
<0.0001
PA 121 (51.2) 115 (58.1) 9 (60.6) 54 (29.4) -51.5% PCV10
(2011–14)
<0.0001
� Impact of PCV as calculated by the relative reduction in proportion of VT from pre-vaccine period to post-vaccine period
https://doi.org/10.1371/journal.pone.0206927.t002
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a pneumococcal carrier, yet, only 42.7% of those parent-child carrier pairs had an identical
serotype on screening. In both regions, once PCV was implemented, none of the VT13 carrier
parents had a child who carried a VT13 strain.
Discussion
We have previously reported the effects of PCV7 by comparing two closely related populations
in which PCV7 was implemented in one but not yet in the other [7]. In this study, we con-
ducted an additional surveillance following the introduction of PCV10 to the previously
Table 3. Prevalence of S. pneumoniae VT13 serotypes in the two regions by year.
EJ PA
2009 2010 2011 2014 P-trend 2009 2010 2011 2014 P
N
%
N
%
N
%
N
%
2009–2014 N
%
N
%
N
%
N
%
2011–2014
VT13 serotypes
19F 16 9 5 0 43 27 25 11
16.00 9.89 5.75 0.00 <0.0001 19.46 13.64 15.63 5.98 0.0036
14 9 4 3 2 19 9 13 13
9.00 4.40 3.45 2.27 0.0320 8.60 4.55 8.13 7.07 0.7107
6B 13 9 7 0 8 14 8 2
13.00 9.89 8.05 0.00 0.0012 3.62 7.07 5.00 1.09 0.0494
23F 6 1 5 2 16 18 16 4
6.00 1.10 5.75 2.27 0.4348 7.24 9.09 10.00 2.17 0.0020
9V 1 0 1 1 4 6 2 3
1.00 0.00 1.15 1.14 0.7331 1.81 3.03 1.25 1.63 1.0000
4 0 0 0 0 1 1 0 2
0.00 0.00 0.00 0.00 0.45 0.51 0.00 1.09 0.5010
18C 2 1 0 0 0 0 2 0
2.00 1.10 0.00 0.00 0.0867 0.00 0.00 1.25 0.00 0.2156
Total VT7 47 24 21 5 91 75 66 35
47.00 26.37 24.14 5.69 < .0001 41.18 37.88 41.25 19.02 < .0001
7F 0 0 0 0 0 1 0 0
0.00 0.00 0.00 0.00 0.00 0.51 0.00 0.00
1 0 0 0 0 0 0 0 0
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
5 1 0 0 0 0 0 1 0
1.00 0.00 0.00 0.00 0.1998 0.00 0.00 0.63 0.00 0.4651
Total VT10 48 24 21 5 91 76 67 35
48.00 26.37 24.14 5.68 < .0001 41.18 38.38 41.88 19.02 < .0001
6A 11 5 4 0 21 25 17 9
11.00 5.49 4.60 0.00 0.0012 9.50 12.63 10.63 4.89 0.0448
19A 3 2 1 1 5 9 6 3
3.00 2.20 1.15 1.14 0.2919 2.26 4.55 3.75 1.63 0.3130
3 0 1 1 3 4 5 7 7
0.00 1.10 1.15 3.41 0.0569 1.81 2.53 4.38 3.80 0.7893
Total VT13 62 32 27 9 121 115 97 54
62.00 35.16 31.03 10.23 < .0001 51.75 58.08 60.63 29.35 < .0001
P-values presented include P-trend for EJ, from 2009–2014, and univariate p-value for pre- to post-vaccine period (2011–2014) for PA.
https://doi.org/10.1371/journal.pone.0206927.t003
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unvaccinated population. This allowed us to assess the impact of different PCVs on pneumo-
coccal carriage among children and their parents and the effects of the different vaccination
programs. To overcome seasonal variability, all surveillances took place during spring-
Table 4. Prevalence of S. pneumoniae Non-VT13 serotypes in the two regions by year.
EJ PA
2009 2010 2011 2014 P-trend 2009 2010 2011 2014 P
N
%
N
%
N
%
N
%
2009–2014 N
%
N
%
N
%
N
%
2011–2014
Non-VT13 serotypes�
11A/D 3 5 4 13 8 8 5 12
3.00 5.49 4.60 14.77 0.0036 3.62 4.04 3.13 6.52 0.1471
19B/C 0 0 4 7 0 1 0 12
0.00 0.00 4.60 7.95 0.0004 0.00 0.51 0.00 6.52 0.0005
25/38 0 3 1 5 0 2 1 4
0.00 3.30 1.15 5.68 0.0366 0.00 1.01 0.63 2.17 0.3775
35B 4 2 7 5 10 3 4 8
4.00 2.20 8.05 5.68 0.2859 4.52 1.52 2.50 4.35 0.3936
15B/C 3 6 11 4 15 7 5 6
3.00 6.59 12.64 4.55 0.3204 6.79 3.54 3.13 3.26 0.9430
10 A/B 2 1 1 4 4 5 1 6
2.00 1.10 1.15 4.55 0.2764 1.81 2.53 0.63 3.26 0.1276
12F 0 1 0 3 0 0 1 6
0.00 1.10 0.00 3.41 0.0603 0.00 0.00 0.63 3.26 0.1276
22F 0 0 0 3 0 1 1 2
0.00 0.00 0.00 3.41 0.0166 0.00 0.51 0.63 1.09
23A 1 3 2 3 2 0 1 7
1.00 3.30 2.30 3.41 0.3711 0.90 0.00 0.63 3.80 0.0724
15A/F 1 7 1 3 4 5 6 8
1.00 7.69 1.15 3.41 0.8646 1.81 2.53 3.75 4.35 0.7796
40 0 0 0 2 0 0 0 6
0.00 0.00 0.00 2.27 0.0508 0.00 0.00 0.00 3.26 0.0322
21 0 0 0 2 1 1 0 1
0.00 0.00 0.00 2.27 0.0508 0.45 0.51 0.00 0.54 1.0000
9N/L 0 0 2 2 1 1 1 1
0.00 0.00 2.30 2.27 0.0603 0.45 0.51 0.63 0.54 1.0000
6C 0 4 3 2 1 3 2 0
0.00 4.40 3.45 2.27 0.3711 0.45 1.52 1.25 0.00 0.2156
23B 1 2 1 2 2 1 2 7
1.00 2.20 1.15 2.27 0.6282 0.90 0.51 1.25 3.80 0.1836
17F 4 4 4 0 7 5 5 6
4.00 4.40 4.60 0.00 0.1646 3.17 2.53 3.13 3.26 0.9430
7B/C 1 0 0 0 0 1 0 5
1.00 0.00 0.00 0.00 0.1990 0.00 0.51 0.00 2.72 0.0637
Total
non-VT13
38 59 60 79 100 83 63 130
38.00 64.84 68.97 89.77 < .0001 45.25 41.92 39.38 70.65 < .0001
P-values presented include P-trend for EJ, from 2009–2014, and univariate p-value for pre- to post-vaccine period (2011–2014) for PA.
�Included in the Table are non-VT13 serotypes that consisted of at least 4% of serotypes in any year or region, or if a change in proportion was observed (p<0.1).
https://doi.org/10.1371/journal.pone.0206927.t004
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summer. This could explain the relatively low carriage rates on one hand, but assured that the
changes observed were not confounded by seasonality.
The main vaccine impact of PCV implementation was the significant decrease in VT
serotypes.
More so, we show that a reduction of ~50% in VT13 serotypes was observed within three
years of implementation of PCV, whether PCV7 or PCV10 were used. This reduction was sim-
ilar, despite slightly different vaccine coverage rates (with 85% vaccine coverage of<2y in PA
vs. 92% coverage in EJ). Comparing the impact of PCV13 is only partially accurate, since
PCV13 was introduced after a significant impact of PCV7 was observed. Yet, an additional
67% decrease in VT13 was observed 3 years after PCV13 replaced PCV7.
There is controversy over the advantage of PCV13 compared to PCV10. While some studies
reported higher effectiveness and cost-effectiveness of PCV13 compared to PCV10 [9–11] due
to its greater coverage, one study reported 97% effectiveness against VT-IPD for PCV10, with
only 86% effectiveness for PCV13 [12] and other studies [13–15] showed no differences
between them. The disparities in results of different studies, particularly regarding the effect
on 19A, which was shown to emerge following PCV10 in some studies but decrease, in other
studies, could be attributed to differences in the study design, different outcomes assessed (car-
riage, IPD, etc.), or different vaccine coverage. Alternatively, the differences could be due to
differences in background circulating clones in the different geographic regions.
Particularly interesting is the comparison of the impact of the different PCVs on serotypes
covered by one vaccine, but not the other (serotypes 3, 6A and 19A). Serotype 6A has been
repeatedly reported to decrease following PCV7 or PCV10 implementation [14, 16–20], proba-
bly due to cross-protection by 6B in PCV7/PCV10. Serotype 19A, which is not included in
either PCV7or PCV10, could similarly be cross-protected by 19F which is included in both
these vaccines. However, only modest protection has been suggested [21]. Moreover, PCV7
introduction in many countries, led to emergence of serotype 19A both in carriage and in IPD
Table 5. S. pneumoniae carriage among parents.
EJ PA
n (%) n (%)
Parent carriage 48/1267 (3.8) 91/2414 (3.8)
Strains available for serotyping 40 86
VT7 7/40 (17.5) 15/86 (17.4)
VT10 7/40 (17.5) 16/86 (18.6)
VT13 13/40 (32.5) 24/86 (27.9)
Non-VT13 27/40 (67.5) 62/86 (72.1)
Child also S. pneumoniae carrier 31/40 (77.5) 55/86 (64.0)
Child also carrier of the same serotype 13/40 (32.5) 19/86 (22.1)
Among VT13 carrier parents (n = 13) (n = 24)
Child also S. pneumoniae carrier 6/13 (46.2) 14/24 (58.3)
Child also carrier of the same serotype 2/13 (15.4) 6/24 (25.0)
Pre-vaccine period� 2/2 (100.0) 6/12 (50.0)
Post-vaccine period� 0/4 (0.0) 0/2 (0.0)
Among non-VT13 carrier parents n = 27 n = 62
Child also S. pneumoniae carrier 15/27 (55.6) 41/62 (66.1)
Child also carrier of the same serotype 11/27 (40.7) 13/62 (21.0)
� Pre-vaccine period in EJ included data from 2009 and in PA from 2009–11. Post-vaccine period in EJ included data
from 2010–14 and in PA from 2014
https://doi.org/10.1371/journal.pone.0206927.t005
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[22–24], yet, we did not observe emergence of 19A in EJ after PCV7 and before PCV13 was
implemented. Similarly a nationwide IPD surveillance study in Israel did not report 19A
increase following PCV7 introduction among children or adults [25, 26]. A plausible explana-
tion could be the rapid transition from PCV7 to PCV13 within less than 2 years in Israel, or a
different clonal background distribution.
In contrast to PCV7, the impact of PCV10 on serotype 19A is much more controversial.
Several studies reported PCV10 effectiveness against serotype 19A [12, 13, 27], while other
studies reported emergence of serotype 19A following PCV10 introduction [14, 28–31]. Here,
we report that serotype 19A did not emerge, or rather tended to decrease following PCV10
implementation in PA. However, it is important to note that these are only short-term (three
years) observations, and longer follow-up is required to determine the long-term impact of
PCV10 on serotype 19A.
The last of the three additional serotypes not included in PCV10 is serotype 3. Serotype 3 is
unique in many aspects, heavily encapsulated with a mucoid phenotype, highly resistant to
phagocytosis. While some have suggested that despite this it is not invasive [32], others have
reported it to be highly invasive, with high case fatality ratios, particularly in adults [33, 34].
Many studies from different geographical regions have reported ineffectiveness of PCV13
against serotype 3 [14, 35–38], although a few have reported decrease in serotype 3 following
PCV13 implementation [39, 40]. We show a nearly significant increase in serotype 3 following
PCV13 implementation in EJ (p = 0.056) and no change after PCV10 implementation in PA.
Whether serotype 3 will eventually decrease in a longer follow-up is yet to be seen.
The relatively stable prevalence of S. pneumoniae carriage despite the significant reduction
in VT strains is attributed to the replacement by non-VT strains as previously described [41–
45]. Serotype replacement is a universal phenomenon in which non-VT serotypes emerge and
replace VT serotypes with geographic variability [42]. The emerging serotypes we observed fol-
lowing the two different vaccination policies were somewhat similar.
In EJ, the most notable emerging non-VT serotypes were 11A/D, 19B/C, 25/38, 40, 21, 9N/
L and 12F and in PA they were 19B/C, 40, 23A and 7B/C. A study in Massachusetts, USA
reported that several years following PCV7 implementation, serotypes 19A, 6A, 15B/C, 35B,
and 11A emerged [46]. In Northern Japan, serotypes 15A, 23A, 11A, 10A and 35B accounted
for the majority of non-VT13 serotypes after the introduction of PCV13 [47]. Serotype 6C was
shown to decline following PCV13 implementation but not PCV7 or PCV10 [19, 38, 48, 49].
Interestingly, we observed emergence of 6C following PCV7 implementation, but a decrease
after either PCV13 or PCV10 implementation.
Parental nasopharyngeal pneumococcal carriage was rare in our population. Carriage rates
in adults were reported to be less than 10%, but higher rates were found among adults with
children at home [50]. An explanation of the relatively low carriage rates we detected could be
that we determined carriage via nasopharyngeal swabbing, while recent reports suggested
higher yield in adults when swabbing both pharynx and nasopharynx or adding salivary testing
[51–53].
While sixty percent of the carrier parents had a carrier child, only 42.7% of those parent-
child co-carrier pairs had an identical serotype. Similar dis-concordance was previously
reported among adults in Israel, where intra-familial transmission could not be demonstrated
[54]. Children were shown to carry pneumococcal strains for months, while adults typically
carry pneumococci for only very short durations [55]. Yet, this does not essentially explain the
relative dis-concordance of serotypes between children and their parents. The difference
between serotypes carried by children’s and their parents’ could be due to the difference of the
direct PCV impact and the indirect (herd effect) impact, on their parents, particularly the
potential time lag of the effects.
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Our study has a few limitations, mainly due to its design as an observational study. First,
vaccination policies were implemented at different times, PCV7/13 in 2009/2010 in EJ, and
PCV10 in 2011 in PA. Second, while the two compared populations are closely related, they
differed in several variables that were adjusted for. Third, the overall carriage in the children
was relatively low, probably due to the ‘off season’ periods we chose, i.e. spring and summer,
when carriage of pneumococci is lower. This was intentional in order to overcome seasonal
variability, but limited the power to detect some differences. Last, this study only reports the
short-term impact of the vaccines and to assess the long-term differences between the vaccines,
longer follow-up is needed.
In conclusion, the unique settings of this study allowed us compare the initial effects of
PCV13 and PCV10 in two closely related populations that live in two geographically proximate
regions, under two different health authorities. Despite the short follow-up interval after
implementation of either PCV13 in EJ or PCV10 in PA, a dramatic decrease in the VT13 sero-
types (including serotypes 6A and 19A but not serotype 3) was observed. Replacement by non-
VT13 was also observed in both populations regardless of the vaccination used. Longer follow-
up is needed to compare the long-term effects.
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